Canature Health Technology Group Co., Ltd. Class A

Canature Health Technology Group Co., Ltd. Class A

SSZSE:300272
5.19
CNY
+0.04
(+0.78%)
-0.03EPS
3.71BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.55
0.65
0.8
1.14
1.22
1.58
1.78
2.24
2.59
2.87
2.98
3.04
3.17
3.03
Basic EPS, GAAP
0.1
0.11
0.13
0.16
0.1
0.61
0.17
0.05
0.18
0.16
0.24
0.12
0.1
-0.08
Free Cash Flow per Basic Share
-0.17
0.03
-0.14
-0.2
-0.14
0.1
0.09
0.18
0.2
0.11
0.52
0.28
0.27
- -
Dividend per Share
0.08
0.05
0.03
0.06
0.08
0.09
0.15
0.08
0.07
0.12
0.14
0.32
0.23
0.17
Book Value per Share
0.85
0.93
1.06
1.18
1.42
1.99
2.05
2.03
2.08
1.89
2.25
2.14
2.06
1.98
Tangible Book Value per Share
0.65
0.73
0.49
0.46
0.68
1.71
1.52
1.53
1.55
1.4
1.82
1.69
1.64
1.57
Basic Weighted Avg Shares
571
578
569
565
580
571
591
528
583
579
562
566
580
612
Sales/Revenue/Turnover
311
375
457
643
708
901
1,053
1,181
1,511
1,661
1,672
1,724
1,841
1,858
Operating Margin (%)
20.78
19.6
16.08
12.99
4.24
6.76
11.76
13.85
9.92
8.63
10.21
9.52
11.36
9.83
Depreciation Expense
9
11
18
33
53
32
30
37
52
76
77
84
93
- -
Net Income, GAAP
57
64
76
90
58
348
101
26
105
93
132
70
56
-51
Effective Tax Rate (%)
15.36
15.52
12.46
14.88
49.84
7.42
32.06
23.79
19.51
13.34
3.35
17.65
27.33
315.15
Profit Margin (%)
18.31
17.14
16.64
14.04
8.2
38.62
9.55
2.24
6.94
5.57
7.92
4.08
3.04
-2.75
Working Capital
209
428
110
-425
103
198
132
181
232
105
252
71
-110
-30
LT Debt
- -
- -
33
26
15
- -
26
46
41
85
222
450
241
279
Total Equity
498
771
894
1,177
1,728
1,178
1,229
1,214
1,252
1,118
1,371
1,326
1,363
1,337
Return on Invested Capital (%)
11.34
10.43
8.33
6.76
0.31
20.25
7.22
2.29
7.79
5.83
7.59
4.28
3.04
-0.57
Return on Capital (%)
10.98
9.23
8.86
8.09
6.65
21.62
6.09
0.89
6.75
6.04
6.78
2.83
2.46
-7
Return on Common Equity (%)
11.86
12.58
13.32
14.02
7.77
35.33
8.55
2.23
8.84
8.07
11.09
5.55
4.48
-4.13

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,250
1,165
1,258
LT Borrowings
189
245
247
LT Finance Leases
52
43
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
611
611
611
Market Capitalization
4,928
3,216
3,706

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,578
1,583
1,674
Cash, Cash Equivalents & STI
1,001
991
1,072
Accounts Receivable, Net
215
231
221
Inventories
286
295
322
Total Current Liabilities
1,671
1,620
1,704
Payables & Accruals
- -
- -
- -
ST Debt
1,250
1,165
1,258
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.44%
2.92%
2.83%
Free Cash Flow
22.23%
61.26%
-3.91%
Net Income, GAAP
59.91%
52.2%
-20.43%
Sales/Revenue/Turnover
15.56%
9.68%
6.77%
Total Cash Common Dividend
33.12%
37.1%
-27.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
381
448
425
434
1,724
2025
413
484
- -
485
1,841
2026
418
504
451
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.06
0.05
- -
0.12
2025
0.04
0.08
- -
-0.06
0.1
2026
0.01
0.06
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.11
0.06
0.08
0.32
2025
0.01
0.05
- -
0.07
0.23
2026
0.02
0.06
0.01
- -
- -

Company Description

CEO
Ya Ming Qu
Full Time Employees
1,510
Sector
Producer manufacturing
Industry
Industrial machinery
Address
No. 518, Chuanda Road Shanghai SH China 201299
IPO Date
Oct 20, 2011
Business
Canature Health Technology Co., Ltd., founded in 2015 and headquartered in Shanghai, China, is a leading manufacturer and provider of water treatment appliances and related products. The company's core product portfolio includes water softeners; reverse osmosis (RO) systems and membranes; control valves; pressure tanks; water filters; and water dispensers. Canature designs, manufactures, and markets over 20 series and more than 80 models of water softener cabinets, reverse osmosis systems with advanced membrane technology, and multi-port control valves certified to international standards such as NSF, CE, RoHS, and ACS. Its products serve residential, commercial, and light industrial customers across domestic and international markets, with approximately 65% of annual revenue generated from overseas operations through OEM production and sales framework agreements. In recent developments, Canature Health Technology has signed a significant share acquisition framework agreement with Original Energy Cell, reflecting its strategic focus on expanding upstream and downstream capabilities in cell storage and related ecological enterprises. The company continues to integrate business and office systems with advanced large model technologies and is investing in the intelligent upgrade and expansion of its health water purification equipment production line, with an adjusted completion timeline to November 2026. It actively pursues technological innovation, including new product launches centered on atomization technology for inhalation therapy and beauty atomization segments, complementing its traditional water purification business. Canature also emphasizes compliance with international certifications and standards to maintain its competitive edge globally. The company’s strategic positioning as a health technology-focused entity differentiates it from pure equipment manufacturers. It leverages manufacturing cost advantages in China while navigating global supply chain challenges. Canature’s recent operational emphasis includes expanding market penetration through enhanced sales channels and local sales teams, diversifying into new business frontiers like inhalation drug delivery devices, and pursuing environmental certifications and quality management system standards such as ISO 9001 and ISO 14001. These initiatives underscore the company’s commitment to sustainable growth and innovation within the global water treatment and health technology markets.